Karyopharm's endometrial cancer trial misses primary endpoint

July 30, 2026 4:05 PM

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced that its Phase 3 XPORT-EC-042 trial evaluating selinexor as a maintenance therapy in patients ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found